Navigation Links
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
Date:3/27/2008

FDA Approves Label Revisions Recommending New Weight-Based Dosing Regimen

KENILWORTH, N.J., March 27 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP) today reported that the U.S. Food and Drug Administration (FDA) has approved label revisions for PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for chronic hepatitis C, recommending weight-based dosing of REBETOL (800-1400 mg daily) based on patient body weight. The revised label also recommends a shorter, 24-week course of the combination therapy for patients with chronic hepatitis C virus (HCV) genotype 2 or 3.

The revisions represent the first FDA approval of a 1400 mg ribavirin dose and the widest ribavirin dosing range approved for use in combination with peginterferon for treating chronic hepatitis C in patients with compensated liver disease.

The label changes are based on the results of the WIN-R trial,(1) the largest U.S. hepatitis C study, conducted in more than 4,900 patients. The study showed that PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient body weight) resulted in a significantly higher sustained virologic response (SVR)(2) compared to PEGINTRON in combination with a flat 800 mg daily dose of REBETOL, the previously labeled dose. Importantly, the study reported low relapse rates consistent with other PEGINTRON studies.(3,4)

"PEGINTRON and weight-based ribavirin was significantly more effective than flat-dosed ribavirin, especially in genotype 1 patients, and provided consistent efficacy across all weight groups," said WIN-R principal investigator Ira M. Jacobson, M.D., Vincent Astor Professor of Clinical Medicine at Weill Medical College of Cornell University and chie
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
4. Obesity-Related Hormone is Higher in Children with Down Syndrome
5. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
6. BSGI Posts Higher Sensitivity than Mammography or MRI for the Detection of Ductal Carcinoma In Situ
7. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
8. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
9. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
10. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
11. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 Aspire Technology Partners ... Excellence Gold Star from Cisco. This designation recognizes Aspire for ... United States of America . "Achieving exceptional ... John C. Harris , President and CEO of Aspire. ... customers with their Gold Star award and are proud to ...
(Date:8/1/2014)... 2014 According to the ... Closure, Anti infective), Basic (Films, Cleansing), Advanced (Hydrogels, ... Substitutes), Pressure Relief Devices, NPWT) - Global Forecast ... Market is expected to reach $18.3 Billion by ... a CAGR of 3.2% from 2014 to 2019. ...
(Date:8/1/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... 3 study evaluating ISIS-SMN Rx in infants with ... of infant mortality. Isis plans to dose the first ... at which time Isis will earn an $18 million ... Phase 3 study, ENDEAR, is the first of several ...
Breaking Medicine Technology:Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5
... Crowds of politicians, patients and physicians gathered on ... Pedro Sula, Honduras, last week to celebrate the inauguration ... Hospital para Ninos Quemados y Cirugia Pediatrica Ruth Paz. ... in Honduras and in Central America. The facility,s establishment ...
... organizations in highly regulated industries, such as pharmaceuticals and ... plans effectively and safely. However, 50% of companies are ... on sites, such as Google, Twitter, and LinkedIn. ... social media as part of a marketing strategy employ ...
Cached Medicine Technology:Carolinas HealthCare System (CHS) Contributes to First Children's Burn Hospital in Central America 2Carolinas HealthCare System (CHS) Contributes to First Children's Burn Hospital in Central America 3Pharmaceutical, Utility Companies Cautiously Add Social Media to Marketing Plans 2
(Date:8/1/2014)... Recently, iFitDress.com, one of the most famous dress suppliers ... top bridesmaid dresses online. At the moment, all the ... 52% off. According to the company’s senior spokesman, the special ... The company’s stock is limited. Those who are thinking of ... soon as possible. All its products are delicately made by ...
(Date:8/1/2014)... University School of Medicine in St. Louis helps explain ... frequently are more harmful than similar tumors in females. ... are diagnosed twice as often in males, who suffer ... as long. , The researchers found that retinoblastoma protein ... significantly less active in male brain cells than in ...
(Date:8/1/2014)... New York, New York (PRWEB) August 01, 2014 ... ) filed in the wake of the 2012 ... continue to move forward in New Jersey’s Bergen ... to documents filed in the proceeding, the Court ... Order of Confidentiality governing any and all hard ...
(Date:8/1/2014)... New York (PRWEB) August 01, 2014 ... ) on behalf of women who allegedly experienced the ... power morcellators in gynecological surgeries, Bernstein Liebhard LLP notes ... withdraw a number of power morcellators marketed by its ... report from The New York Times, some critics of ...
(Date:8/1/2014)... Rochelle, NY, August 1, 2014Lesbian, gay, bisexual, and transgender ... the same problems as some of their heterosexual and ... they often face additional physiological and legal challenges ... recent advances in assisted reproduction options is presented in ... Future Possibilities ," published in LGBT Health ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2
... Insurance Agents, their Approach Could Save ... Hundreds of Millions of Gallons, KIRKLAND, Wash., ... That,s the experience of LTC Financial Partners LLC (known,in the industry ... agencies. As a result of pro-environment steps now being,taken, the organization ...
... uninsured young adults in the United States rose to 13.7 ... 19-to-29 age group one of the largest and fastest-growing segments ... updated report from The Commonwealth Fund, 38 percent of high ... of college graduates will spend some time uninsured in the ...
... Top 5 Children,s Hospital, CLEVELAND, May 30 ... Center is once again ranked as a top,five children,s ... year, the,first time the publication ranked pediatric subspecialties, Rainbow ... in the country for,neurology/neurosurgery and respiratory disorders. Rainbow is ...
... area doctors,and six others have been charged in ... fraud schemes totaling $56 million, the Department of,Justice ... Southern,District of Florida announced today., One indictment ... Dr.,Ronald Harris, 57, and Enrique Gonzalez, 62, conspired ...
... May 29 The hospitals, physicians,pharmaceutical companies, and ... healthcare system will be spending $55 billion on,telecommunications ... new market,research study released by the Insight Research ... the US healthcare industry on,telecommunications services will grow ...
... help honorably,discharged veterans become small business owners through ... designed to help business-minded veterans start on the,right ... Dec. 31, 2008, GNC,will offer a 25 percent ... additional benefits, including a 50,percent discount on the ...
Cached Medicine News:Health News:Long Term Care Insurance Leader Goes Green, Targeting a Million Gallons of Gasoline Saved Per Year 2Health News:Long Term Care Insurance Leader Goes Green, Targeting a Million Gallons of Gasoline Saved Per Year 3Health News:Young adults at risk: 13.7 million lack health insurance coverage 2Health News:Young adults at risk: 13.7 million lack health insurance coverage 3Health News:Rainbow Babies & Children's Hospital NICU Ranks #2 in Country 2Health News:Rainbow Babies & Children's Hospital NICU Ranks #2 in Country 3Health News:Three Miami Area Doctors and Six Others Charged in $56 Million Health Care Fraud Schemes 2Health News:Three Miami Area Doctors and Six Others Charged in $56 Million Health Care Fraud Schemes 3Health News:Three Miami Area Doctors and Six Others Charged in $56 Million Health Care Fraud Schemes 4Health News:Three Miami Area Doctors and Six Others Charged in $56 Million Health Care Fraud Schemes 5Health News:Healthcare Industry Spending on Telecommunications Services Hits $55 Billion Over Next Five Years, Says Insight Research 2Health News:Veterans to Receive Business Discounts Through GNC's New Veterans Franchising Opportunity 2
... a long term, quality solution based on ... posterior stabilized and anatomically correct cruciate retaining ... flexibility needed to address patients' needs. In ... keeps the user in mind and promotes ...
... Knee system was designed to enhance ... articulating surfaces, to minimize contact stress ... a well balanced knee with normalized ... MJS Knee system allows maximum surgical ...
... The FluoroNav Virtual Fluoroscopy ... Navigation Technologies has incorporated ... exciting technology features such ... and three-dimensional models of ...
... Radionics' new OmniSight image guided ... while maintaining simplicity in design and ... allowing the neurosurgeon to localize critical ... This new system gives surgeons an ...
Medicine Products: